Research news

Research news

1 August 2019

Type 2 diabetes is an increasingly common metabolic disorder in men, due to the increasing prevalence of obesity and hypogonadism. Type 2 diabetes increases the risk of developing a number of serious health problems, resulting in higher medical care costs, reduced quality of life and premature death. In this editorial we present two new studies showing that hypogonadism markedly increases risk for development of type 2 diabetes, and in men with existing type 2 diabetes, hypogonadism markedly increases mortality.

These two studies highlight the need for raising the awareness of hypogonadism and its health consequences, and that testosterone therapy prevents the development of type 2 diabetes as well as reduces mortality in men with existing type 2 diabetes.

Read article
1 July 2019

One main reason why few men with hypogonadism receive testosterone therapy is that urologists and other physicians only check testosterone if a patient proactively complains about and suffers from erectile dysfunction. However, men with cardiovascular risk factors (obesity, type 2 diabetes, metabolic syndrome) – even if they don’t suffer or complain about bothersome symptoms – also have a high prevalence of hypogonadism. Therefore it is critical that HCPs actively ask about sexual (dys)function in men with cardiovascular risk factors or established cardiovascular disease.

Read article
15 June 2019

The Nebido® Treatment Tracker is a tool designed to help HCPs improve patient adherence to Nebido treatment. The British Society for Sexual Medicine (BSSM) guideline recommends initiating testosterone therapy only in conjunction with weight-loss advice and lifestyle modification.  Considering that lifestyle change is notoriously difficult for patients to achieve and maintain, and the need for long-term adherence to Nebido® treatment in order to achieve the full spectrum of health benefits, the Nebido® Treatment Tracker was developed.

Read article
1 June 2019

We all know Type 2 diabetes is a huge burden on health systems and a leading cause of patient suffering. Remission of Type 2 diabetes is therefore big news, and without bariatric surgery, it is considered very rare. However, we recently reported remission in an obese man being treated with Nebido for his underlying hypogonadism, which is highly prevalent in men with Type 2 diabetes.

Read article
16 May 2019

Type 2 diabetes is a costly disease that is highly prevalent among men with hypogonadism. Unless given testosterone therapy, these men often struggle to achieve glycemic targets.

Many studies have shown that testosterone therapy increases insulin sensitivity and reduces HbA1c. These improvements in glycemic control are particularly after long-term testosterone therapy lasting for at least 6 years. This suggests that there may be a chance to prevent type 2 diabetes with testosterone therapy in men with hypogonadism.

Read article
15 May 2019

Is it possible to stop or delay the onset of diabetes in hypogonadal men with testosterone therapy?

The “Testosterone 4 Diabetes Mellitus” study, also known as the T4DM trial, is a randomised, double-blind, placebo-controlled trial – the gold standard study method - designed to find out if testosterone therapy with Nebido®/Reandron® combined with lifestyle intervention (Weight Watchers®) for 2 years versus lifestyle intervention alone, improves glucose tolerance and reduces incidence of type 2 diabetes.

The T4DM trial will be the first ever RCT to specifically investigate the effects of testosterone therapy on motivation / behaviour and telomere length, a biomarker of aging.

Read article
15 February 2019

A prerequisite for successful testosterone therapy is that the therapeutic testosterone target level of 15-30 nmol/mL is maintained long-term in order for symptom resolution and health benefits to occur. Therefore, adherence to testosterone therapy is critical.

New data showing superior adherence to testosterone therapy with long-acting testosterone undecanoate suggest that treatment with Nebido is more likely to confer long-term treatment benefits compared to gels and shot-acting testosterone preparations.

Read article
15 January 2019

Due to a high prevalence of hypogonadism in type 2 diabetic men, current guidelines recommend to test for low levels of testosterone in diabetic men.

A progressive reduction in waist circumference, along with a progressive improvement in erectile function as well as markedly reduces need for diabetes medications was shown in a 4-year follow-up analysis of the BLAST study in men with hypogonadism and type 2 diabetes who stay on long-term testosterone therapy with testosterone undecanoate.

Read article
15 December 2018

Does it matter which testosterone preparation is prescribed for testosterone therapy? This is a common question among HCPs as well as patients. A new meta-analysis shows that testosterone therapy with injectable testosterone preparations results in larger muscle and strength gains compared to transdermal testosterone preparations. This has important implications for the growing population of men with hypogonadism, who are at high risk of lean (muscle) mass loss, obesity, diabetes and sarcopenia.

    Read article
    23 November 2018

    The Testosterone Trials show that testosterone therapy confers significant and clinically meaningful health benefits in older men with low testosterone levels. Even though the Testosterone Trials aimed to recruit men with hypogonadism due to no apparent reason other than age, in fact the majority of enrolled men were obese and more than one third had type 2 diabetes. Obesity, metabolic syndrome and/or type 2 diabetes are stronger risk factors for hypogonadism than aging per se. Consequently, the Testosterone Trials provide compelling evidence that testosterone therapy confers significant benefits in the growing population of men with obesity and/or type 2 diabetes.

    Read article
    • PP-NEB-ALL-0347-1

    Copyright © 2019,
    Bayer AG

    This website is intended to provide information to an international audience outside the USA and UK.

    Page last modified Mon, 16/09/2019

    Bayer logo